Shares of Health Care sector company BioMarin Pharmaceutical moved 0.7% today, and are now trading at a price of $62.46. The Large-Cap stock's daily volume was 674,696 compared to its average volume of 1,697,921. The S&P 500 index returned a -0.0% performance.
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company is based in San Rafael and has 3,040 full time employees. Its market capitalization is $11,978,329,088.
28 analysts are following BioMarin Pharmaceutical and have set target prices ranging from $65.0 to $126.0 per share. On average, they have given the company a rating of buy. At today's prices, BMRN is trading -34.95% away from its average analyst target price of $96.02 per share.
Over the last year, BMRN shares have gone down by -24.4%, which represents a difference of -34.2% when compared to the S&P 500. The stock's 52 week high is $94.85 per share and its 52 week low is $52.93. With average free cash flows of $114.7 Million that have been growing at an average rate of 54.3% over the last 5 years, BioMarin Pharmaceutical declining stock performance may not be reflective of the quality of its underlying business.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2024 | 572,841 | 85,424 | 487,417 | 679.02 |
| 2023 | 159,259 | 96,691 | 62,568 | 13.88 |
| 2022 | 175,902 | 120,959 | 54,943 | -73.71 |
| 2021 | 304,536 | 95,578 | 208,958 | 821.86 |
| 2020 | 85,365 | 114,312 | -28,947 | 70.08 |
| 2019 | 48,262 | 145,026 | -96,764 |
